Volume 6.19 | May 22

Mammary Cell News 6.19 May 22, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Sumoylation Pathway Is Required to Maintain the Basal Breast Cancer Subtype
A detailed structure-function analysis identified that sumoylation of TFAP2A blocks its ability to induce the expression of luminal genes. Disruption of the sumoylation pathway by knockdown of sumoylation enzymes, mutation of the SUMO-target lysine of TFAP2A, or treatment with sumoylation inhibitors induced a basal-to-luminal transition, which was dependent on TFAP2A. [Cancer Cell] Abstract | Graphical Abstract
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
PUBLICATIONS (Ranked by impact factor of the journal)

Cell Type-Restricted Activity of hnRNPM Promotes Breast Cancer Metastasis via Regulating Alternative Splicing
The authors uncovered a splicing-mediated pathway that is essential for breast cancer metastasis. They showed that the RNA-binding protein heterogeneous nuclear ribonucleoprotein M (hnRNPM) promotes breast cancer metastasis by activating the switch of alternative splicing that occurs during epithelial-mesenchymal transition. [Genes Dev] Abstract

Wide-Scale Alterations in Interchromosomal Organization in Breast Cancer Cells: Defining a Network of Interacting Chromosomes
The interchromosomal spatial positionings of a subset of human chromosomes was examined in the human breast cell line MCF10A and its malignant counterpart MCF10CA1a. The nine chromosomes selected cover a wide range in size and gene density and compose ~40% of the total human genome. [Hum Mol Genet] Abstract

The ShcA Adaptor Activates AKT Signaling to Potentiate Breast Tumor Angiogenesis by Stimulating VEGF mRNA Translation in a 4E-BP-Dependent Manner
Scientists demonstrate that ShcA-dependent activation of AKT, but not the RAS/MAPK pathway, induces vascular endothelial growth factor (VEGF) production by bolstering VEGF mRNA translation. Accordingly, ShcA drives breast tumor growth and angiogenesis in vivo in a 4E-BP-dependent manner. [Oncogene] Abstract

Involvement of Protein Kinase C α and δ Activities on the Induction of the Retinoic Acid System in Mammary Cancer Cells
Due to the cytostatic and differentiating effects of retinoids, investigators evaluated whether the crosstalk between the retinoid system and the protein kinase C pathway could become a possible target for breast cancer treatment. [Mol Carcinog] Abstract

Conditionally Reprogrammed Normal and Transformed Mouse Mammary Epithelial Cells Display a Progenitor-Cell-Like Phenotype
Scientists demonstrate that mouse mammary epithelial cells isolated from normal mammary glands or from mouse mammary tumor virus-Neu-induced mammary tumors, can be cultured indefinitely as conditionally reprogrammed cells on irradiated fibroblasts in the presence of the Rho kinase inhibitor Y-27632. [PLoS One] Full Article | Press Release

The Anticancer Effect and Mechanism of α-Hederin on Breast Cancer Cells
α-hederin showed strong inhibitory activity on the growth of breast cancer cells and induced apoptosis in these cells. α-hederin induced depolarization of mitochondrial membrane potential which released Apaf-1 and cytochrome c from the intermembrane space into the cytosol, where they promoted caspase-3 and caspase-9 activation. [Int J Cancer] Abstract

Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated with Improved Local Control in Inflammatory Breast Cancer Patients Treated with Postmastectomy Radiation
Investigators examined simvastatin radiosensitization of multiple subtypes of breast cancer cell lines in vitro in monolayer and mammosphere-based clonogenic assays and examined the therapeutic benefit of statin use on local control after postmastectomy radiation among inflammatory breast cancer patients. [Stem Cells Transl Med] Abstract


Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer with Biomarker Analyses
Olaparib has single-agent activity against breast/ovarian cancer in germline BRCA1 or BRCA2 mutation carriers. Researchers hypothesized addition of olaparib to carboplatin can be administered safely and yield preliminary clinical activity. [J Natl Cancer Inst] Abstract

Impact of Adding the Multikinase Inhibitor Sorafenib to Endocrine Therapy in Metastatic Estrogen Receptor-Positive Breast Cancer
A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was conducted. Primary end point was response by RECIST after three months of sorafenib. [Future Oncol] Full Article

Read White Paper: Increase Success Rate Of Compounds In Toxicity Testing
Hierarchy of Breast Cancer Cells: Key to Reverse Dormancy for Therapeutic Intervention
The properties of cancer stem cells and healthy stem cells are functionally similar, thereby posing a challenge to target the dormant cells. The bone marrow is particularly a challenge because the dormant breast cancer cells are close to the endosteum, which is also home to the endogenous hematopoietic stem cells. The authors discuss how research studies could bring an understanding of the cellular and molecular interactions between the cancer stem cells and cells within the bone marrow microenvironment. [Stem Cells Transl Med] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Pfizer to Submit Palbociclib New Drug Application with FDA Based on Final Results of PALOMA-1
Pfizer Inc. announced that it will submit a New Drug Application with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. [Pfizer Inc.] Press Release

Bold Initiative to Transform Cancer Care Established with a $100 Million Gift
Memorial Sloan Kettering Cancer Center announced the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO). Named in honor of Marie-Josée and Henry R. Kravis and the $100 million gift from their foundation, the CMO will enable researchers to speed the translation of new discoveries into routine clinical practice and reshape the design of clinical trials. [Memorial Sloan Kettering Cancer Center]
Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Case Western Reserve University (CWRU) Cancer Stem Cell Conference
August 17-20, 2014
Cleveland, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Research Associates – Pattern Formation during Branching Morphogenesis of the Mammary Gland (Princeton University)

NEW Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Positions – Breast Cancer, Mouse Models, Tumor Microenvironment (National Cancer Institute)

Postdoctoral Training Fellow – Breast Cancer Functional Genomics (Institute of Cancer Research)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

Postdoctoral Fellow – Cancer Biology (University of Cincinnati)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

PhD Position – Breast Cancer Translational Research Laboratory (Jules Bordet Institute)

Postdoctoral Position in Stem Cell and Cancer (Harvard Medical School)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us